Rahnama R, Kizerwetter M, Yang H, Christodoulou I, Guaraca C, Holl N
J Immunother Cancer. 2025; 13(2).
PMID: 39915004
PMC: 11804205.
DOI: 10.1136/jitc-2024-010763.
Upadhyay S, Murugu L, Svensson L
Front Immunol. 2025; 16:1519841.
PMID: 39911389
PMC: 11794523.
DOI: 10.3389/fimmu.2025.1519841.
Ahmad S, Xing K, Rajakaruna H, Stewart W, Beckwith K, Nayak I
bioRxiv. 2025; .
PMID: 39803543
PMC: 11722217.
DOI: 10.1101/2024.12.31.630941.
Zhang M, Loh H, Goh Fang S, Yang Y, Lam K, Xu S
Antibodies (Basel). 2024; 13(4).
PMID: 39727480
PMC: 11672634.
DOI: 10.3390/antib13040097.
Ayalew H, Xu C, Adane A, Sanchez A, Li S, Wang J
Poult Sci. 2024; 104(1):104607.
PMID: 39693955
PMC: 11720616.
DOI: 10.1016/j.psj.2024.104607.
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.
Yao P, Liu Y, Huang G, Hao L, Wang R
Exp Hematol Oncol. 2024; 13(1):118.
PMID: 39633491
PMC: 11616395.
DOI: 10.1186/s40164-024-00583-7.
Charge-based immunoreceptor signalling in health and disease.
Shi X, He X, Xu C
Nat Rev Immunol. 2024; .
PMID: 39528837
DOI: 10.1038/s41577-024-01105-6.
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy.
Fang M, Allen A, Luo C, Finn J
Front Immunol. 2024; 15:1457629.
PMID: 39281684
PMC: 11392856.
DOI: 10.3389/fimmu.2024.1457629.
Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.
Li C, Yu X, Han X, Lian C, Wang Z, Shao S
iScience. 2024; 27(9):110750.
PMID: 39280627
PMC: 11399700.
DOI: 10.1016/j.isci.2024.110750.
The relationship between metabolite mediated immune regulatory imbalance and the occurrence of malignant tumors of bone and articular cartilage: a Mendelian randomization study.
Long K, Gong A, Zheng T, Liu S, Ying Z, Xiao C
Front Immunol. 2024; 15:1433219.
PMID: 39185420
PMC: 11341416.
DOI: 10.3389/fimmu.2024.1433219.
Natural Killer cells at the frontline in the fight against cancer.
Coenon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M
Cell Death Dis. 2024; 15(8):614.
PMID: 39179536
PMC: 11343846.
DOI: 10.1038/s41419-024-06976-0.
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.
Peng L, Sferruzza G, Yang L, Zhou L, Chen S
Cell Mol Immunol. 2024; 21(10):1089-1108.
PMID: 39134804
PMC: 11442786.
DOI: 10.1038/s41423-024-01207-0.
Inhibition of NK cell cytotoxicity by tubular epithelial cell expression of Clr-b and Clr-f.
Fuhrmann B, Jiang J, McLeod P, Huang X, Balaji S, Arp J
Curr Res Immunol. 2024; 5:100081.
PMID: 39113760
PMC: 11303997.
DOI: 10.1016/j.crimmu.2024.100081.
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
Dixon K, Snyder K, Khaw M, Hullsiek R, Davis Z, Matson A
Front Immunol. 2024; 15:1407567.
PMID: 39100677
PMC: 11294090.
DOI: 10.3389/fimmu.2024.1407567.
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity.
Nguyen N, Muller R, Briukhovetska D, Weber J, Feucht J, Kunkele A
Cancers (Basel). 2024; 16(14).
PMID: 39061247
PMC: 11274444.
DOI: 10.3390/cancers16142608.
STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance.
Witalisz-Siepracka A, Denk C, Zdarsky B, Hofmann L, Edtmayer S, Harm T
Front Immunol. 2024; 15:1374068.
PMID: 39034990
PMC: 11257888.
DOI: 10.3389/fimmu.2024.1374068.
Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy.
Arellano-Ballestero H, Zubiak A, Dally C, Orchard K, Alrubayyi A, Charalambous X
J Immunother Cancer. 2024; 12(7).
PMID: 39032940
PMC: 11261707.
DOI: 10.1136/jitc-2023-008717.
A comprehensive analysis of the immune system in healthy Vietnamese people.
Huynh D, Nguyen M, Ngo D, Nguyen X, Nguyen D, Mai T
Heliyon. 2024; 10(9):e30647.
PMID: 38765090
PMC: 11101793.
DOI: 10.1016/j.heliyon.2024.e30647.
Th17 Cell and Inflammatory Infiltrate Interactions in Cutaneous Leishmaniasis: Unraveling Immunopathogenic Mechanisms.
Morales-Primo A, Becker I, Pedraza-Zamora C, Zamora-Chimal J
Immune Netw. 2024; 24(2):e14.
PMID: 38725676
PMC: 11076297.
DOI: 10.4110/in.2024.24.e14.
Engineering immune-evasive allogeneic cellular immunotherapies.
Martin K, Hammer Q, Perica K, Sadelain M, Malmberg K
Nat Rev Immunol. 2024; 24(9):680-693.
PMID: 38658708
DOI: 10.1038/s41577-024-01022-8.